Effect of CYP2C19 genetic polymorphism on drug metabolism and individualized therapy

Abstract

Abstract: CYP2C19 is an important durg-metabolizing enzyme involved in the metabolism of a variety of drugs in vivo. The enzymatic activity is significantly different in different individuals and races. This paper is about the effect of CYP2C19 genetic polymorphism on drug metabolism,in order to lay down a solid theory foundation for the guidance in clinical rational administration, ensure the safety and effectiveness of clinical usage, achieving individualized therapy in its true sense.

Key words: CYP2C19, Genetic polymorphism, Drug metabolism, Individualized therapy

CLC Number:

R969

YAN Fei, XIA Chun-hua, XIONG Yu-qing. Effect of CYP2C19 genetic polymorphism on drug metabolism and individualized therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 949-953.

References

[1] Pestka EL, Hale AM, Johnson BL, et al. Cytochrome P450 testing for better psychiatric care[J]. J Psychosoc Nurs Ment Health Serv, 2007, 45(10): 15-18.
[2] Bertilsson L. Metabolism of antidepressant and neuroleptic Durgs by cytochrome p450: clinical and interethnic aspects[J]. Clin Pharmacol Ther, 2007, 82(5): 606-609.
[3] De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans[J]. J Biol Chem, 1994, 269(22): 15419-15422.
[4] De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin in Japanese[J]. Mol Pharmacol, 1994, 46(4): 594-598.
[5] Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug response to proton pump inhibitors and antidepressants[J]. Clin Pharmacol Ther, 2006, 79(1): 103-113.
[6] Oates NS, Shah RR, Idle JR, et al. Influence of oxidation polymorphism on phenformin kinetics and dynamics[J]. Clin Pharmacol Ther, 1993, 34(6): 827-834.
[7] Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and identification of a new rare CYP2C19 mutant allele[J]. J Pharmacol Experi Ther, 1997, 281: 604-609.
[8] 何楠, 周宏灏. CYP2C19遗传多态性的研究进展[J]. 生理科学进展, 2003, 34(2): 171-174.
[9] 盛海辉, 肖华胜. 细胞色素P450基因多态性与药物代谢[J].国际遗传学杂志, 2008, 31(3): 206-212.
[10] Jiang DC, Bai XR, Zhang QX, et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling[J]. Eur J Clin Pharmacol 2009, 65(12): 1187-1193.
[11] Hunfeld ND, Touw DJ, Mathot RA, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism[J]. Aliment Pharmacol Ther, 2010, 31(1): 150-159.
[12] Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19[J]. Drug Metab Dispos , 2003, 31(10): 1255-1259.
[13] Sim SC, Nordin L, Andersson TML, et al. Association between CYP2C19 polymorp-hism and depressive symptoms[J]. Am J Med Genet B Neuropsychiatr Genet, 2010, 153B(6): 1160-1166.
[14] Scholz L, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype[J]. Br J Clin Pharmacol, 2009, 68(6): 906-915.
[15] Weber WW. The legacy of pharmacogenetics and potential applications[J]. Mutat Res, 2001, 479(1/2): 1-18.
[16] 于洁, 邵宏, 聂小燕, 等. CYP2C19基因多态性对癫痫患者丙戊酸血药浓度的影响[J]. 中国临床药理学与治疗学, 2007, 12(6): 700-704.
[17] Komatsu T, Yamazaki H, Asahi S, et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol:roles of cytochromes P450 2C9, 2C19, and 3A4 [J]. Drug Metab Dispos, 2000, 28(11): 1361-1368.
[18] 齐小涟, 黄越, 王育琴, 等. 苯妥英钠血药浓度与CYP2C19基因多态性关系的研究[J].中国新药杂志, 2004, 13(10): 922-925.
[19] 王育琴, 齐小涟, 黄越, 等. 丙戊酸药物浓度与CYP2C19基因多态性关系的研究[J]. 中国医院药学杂志, 2003, 23(11): 670-673.
[20] Shirai N, Furuta, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric PH[J]. Aliment Pharmacol Ther, 2001, 15(12): 1929-1937.
[21] Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotpye and pharmacokinetics of three proton pump inhibitors in healthy subjects[J]. Pharm Res, 2001, 18(6): 721-727.
[22] 牛春燕, 罗金燕, 王学勤, 等. CYP2C19基因多态性对雷贝拉唑及埃索美拉唑抑酸效应的影响[J]. 中国临床医学, 2004, 11(6): 1002-1004.
[23] Sindrup SH, Brosen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms[J]. Ther Drug Monit, 1993, 15(1): 11-17.
[24] 司天梅,杨琴,刘薏,等. CYP2C19遗传多态性对西酞普兰血药浓度的影响[J]. 中国新药杂志, 2006, 15(15): 1296-1299.
[25] Herrlin K, Yasui-Furudori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedens[J]. Br J Clin Pharmacol, 2003, 56(4): 415-421.
[26] Inomata S, Nagashima A, Ltagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia[J]. Clin Pharmacol Ther, 2005, 78(6): 647-655.
[27] Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics[J]. Science, 1999, 286(5439): 487-491.
[28] Severino G, Del-Zompo M. Adverse durg reactions: role of pharmacogenomics[J]. Pharmacol Res, 2004, 49(4): 363-373.
[29] 齐小涟, 王育琴, 黄越, 等. 丙戊酸药物浓度与CYP2C19基因多态性关系的研究[J]. 中国医院药学杂志, 2003, 23(11): 670-673.